Report Status: Final Quest Be) diagnostics EPSTEIN, JEFFREY Patient Information _ Specimen Information Client Information smen: j : 2 EPSTEIN, JEFFREY Specimen: MR156329E Client #: 78300020 56W5265 Requisition: 0004002 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 64 BRUCE MOSKOWITZ, MD Gender: M Attn: NATIONWIDE ACCOUNT Collected: 01/05/2018 Phone: Received: 01/05/2018 / 22:36 EST Patient ID: 19530120MJE Reported: 01/08/2018 / 23:26 EST Health ID: 857300329085 1249 1411 N FLAGLER DR STE 7100 WEST PALM BEACH, FL 33401-3418 Test Name In Range Out Of Range Reference Range Lab LIPID PANEL CHOLESTEROL, TOTAL 207 H <200 mg/dL MI HDL CHOLESTEROL 28 L >40 mg/dL MI TRIGLYCERIDES 510 H <150 mg/dL MI LDL-CHOLESTEROL mg/dL (calc) MI LDL cholesterol not calculated. Triglyceride levels greater than 400 mg/dL invalidate calculated LDL results. Reference range: <100 Desirable range <100 mg/dL for patients with CHD or diabetes and <70 mg/dL for diabetic patients with known heart disease. LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http: //education.QuestDiagnostics.com/faqg/FAQ164) CHOL/HDLC RATIO 7.44 <5.0 (calc) MI NON HDL CHOLESTEROL 179 H <130 mg/dL (calc) MI For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.2 mg/L TP Average relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk. 1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk. Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary to infection or inflammation. >10.0 Persistent elevation, upon retesting, may be associated with infection and inflammation. HOMOCYSTEINE 13.748 <11.4 umol/L MI Homocysteine is increased by functional deficiency of folate or vitamin B12. Testing for methylmalonic acid differentiates between these deficiencies. Other causes of increased homocysteine include renal failure, folate antagonists such as methotrexate and phenytoin, and exposure to nitrous oxide. CLIENT SERVICES: 866.697.8378 SPECIMEN: MR156329E PAGE | OF 5 Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00304997

--=PAGE_BREAK=--

Report Status: Final (@) Quest & ! Diagnostics EPSTEIN, JEFFREY | Patient Information | Specimen Information | Client Information EPSTEIN, JEFFREY Specimen: MR156329E Client #: 78300020 Collected: 01/05/2018 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 64 Received: 01/05/2018 / 22:36 EST Gender: M Reported: 01/08/2018 / 23:26 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Test Name In Range Out Of Range Reference Range Lab COMPREHENSIVE METABOLIC MI PANEL GLUCOSE $0 65-99 mg/dL Fasting reference interval UREA NITROGEN (BUN) 20 7-25 mg/dL CREATININE 1.10 0.70-1.25 mg/dL For patients >49 years of age, the reference limit for Creatinine is approximately 13% higher for people identified as African-American. eGFR NON-AFR. AMERICAN 71 > OR = 60 mL/min/1.73m2 eGFR AFRICAN AMERICAN 82 > OR = 60 mL/min/1.73m2 BUN/CREATININE RATIO NOT APPLICABLE 6-22 (calc) SODIUM 147 H 135-146 mmol/L POTASSIUM 4.7 3.5-5.3 mmol/L CHLORIDE 112 H 98-110 mmol/L CARBON DIOXIDE 23 20-31 mmol/L CALCIUM 9.8 8.6-10.3 mg/dL PROTEIN, TOTAL 7.3 6.1-8.1 g/dL ALBUMIN 4.3 3.6-5.1 g/dL GLOBULIN 3.0 1.9-3.7 g/dL (calc) ALBUMIN/GLOBULIN RATIO 1.4 1.0-2.5 (calc) BILIRUBIN, TOTAL 0.8 0.2-1.2 mg/dL ALKALINE PHOSPHATASE 56 40-115 U/L AST 22 10-35 U/L ALT 26 9-46 U/L HEMOGLOBIN Alc 5.5 <5.7 % of total Hgb MI For the purpose of screening for the presence of diabetes: <5.7% Consistent with the absence of diabetes 5.7-6.4% Consistent with increased risk for diabetes (prediabetes) > or =6.5% Consistent with diabetes This assay result is consistent with a decreased risk of diabetes. Currently, no consensus exists regarding use of hemoglobin Alc for diagnosis of diabetes in children. According to American Diabetes Association (ADA) guidelines, hemoglobin Alc <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes (ADA). URIC ACID 8.0 4.0-8.0 mg/dL MI Therapeutic target for gout patients: <6.0 mg/dL TSH 3.05 0.40-4.50 mIU/L MI T4 (THYROXINE), TOTAL 7.8 4.5-12.0 mcg/dL MI FREE T4 INDEX (T7) 2.1 1.4-3.8 T3 UPTAKE 27 22-35 % MI CLIENT SERVICES: 866.697.8378 SPECIMEN: MR156329E PAGE 2 OF 5 Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00304998

--=PAGE_BREAK=--

Report Status: Final Quest @) Diagnostics EPSTEIN, JEFFREY Patient Information | Specimen Information _ Client Information EPSTEIN, JEFFREY Specimen: MR156329E Client #: 78300020 Collected: 01/05/2018 MOSKOWITZ, BRUCE W DOB: 01/20/1953, AGE: 64 Received: 01/05/2018 / 22:36 EST Gender: M Patient ID; 19530120MJE Health ID: 857300329085 1249 Reported: 01/08/2018 / 23:26 EST Test Name SED RATE BY MODIFIED WESTERGREN CBC (INCLUDES DIFF/PLT) WHITE BLOOD CELL COUNT RED BLOOD CELL COUNT HEMOGLOBIN HEMATOCRIT MCV MCH MCHC ROW PLATELET MPV ABSOLUTE ABSOLUTE ABSOLUTE COUNT NEUTROPHILS LYMPHOCYTES MONOCYTES ABSOLUTE EOSINOPHILS ABSOLUTE BASOPHILS NEUTROPHILS LYMPHOCYTES MONOCYTES EOSINOPHILS BASOPHILS URINALYSIS, COLOR APPEARANCE SPECIFIC GRAVITY PH GLUCOSE BILIRUBIN KETONES OCCULT BLOOD PROTEIN NITRITE LEUKOCYTE ESTERASE WBC RBC SQUAMOUS EPITHELIAL CELLS BACTERIA HYALINE CAST VITAMIN B12 C-REACTIVE PROTEIN MERCURY, BLOOD COMP LETE In Range Out Of Range 9 6.2 5.17 14.9 43.8 84.7 28.8 34.0 13.7 265 10.3 2895 2331 YELLOW CLEAR 1.023 < OR = 5.0 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NONE SEEN 0-2 NONE SEEN NONE SEEN NONE SEEN 471 1.4 <5 This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. TOTAL IA TESTOSTERONE, MALES (ADULT), TESTOSTERONE, TOTAL, MALES (ADULT), IA In hypogonadal males, 150 L Testosterone, Total, LC/MS/MS, is the recommended assay due to the diminished accuracy of immunoassay at levels below 250 ng/dL. CLIENT SERVICES: 866.697.8378 SPECIMEN: MR156329E Reference Range < OR = 20 mm/h 3.8-10.8 Thousand/uL 4.20-5.80 Million/uL 13.2-17.1 g/dL 38.5-50.0 % 80.0-100.0 fL 27.0-33.0 pg 32.0-36.0 g/dL 11.0-15.0 % 140-400 Thousand/uL 7.5-12.5 fL 1500-7800 cells/uL 850-3900 cells/uL 200-950 cells/uL 15-500 cells/uL 0-200 cells/uL oP dP dP dP dP MI YELLOW CLEAR 1.001-1.035 5.0-8.0 NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE < OR 5 /HPF < OR = 2 /HPF < OR = 5 /HPF NONE SEEN /HPF NONE SEEN /LPF 200-1100 pg/mL <8.0 mg/L <OR=10 mcg/L MI MI AT MI 250-827 ng/dL PAGE 3 OF 5 Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00304999

--=PAGE_BREAK=--

‘C ) Quest Diagnostics” Report Status: Final EPSTEIN, JEFFREY Patient Information _ Specimen Information Specimen: MR156329E EPSTEIN, JEFFREY Collected: 01/05/2018 DOB: 01/20/1953 AGE: 64 Received: 01/05/2018 / 22:36 EST Gender: M Reported: 01/08/2018 / 23:26 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Test Name In Range Out Of Range PSA, This test code (15983) must be collected ina red-top tube with no gel. TOTAL 0.5 The total PSA value from this assay system is standardized against the WHO standard. The test result will be approximately 20% lower when compared to the equimolar-standardized total PSA (Beckman Coulter). Comparison of serial PSA results should be interpreted with this fact in mind. This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not be interpreted as absolute evidence of the presence or absence of disease. CLIENT SERVICES: 866.697.8378 SPECIMEN: MR156329E Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. | Client Information Client #: 78300020 MOSKOWITZ, BRUCE W Reference Range Lab < OR = 4.0 ng/mL MI PAGE 4 OF 5 EFTA00305000

--=PAGE_BREAK=--

Report Status: Final (@ ) Quest Diagnostics” EPSTEIN, JEFFREY Patient Information Specimen Information Client Information Specimen: MR156329E Client #: 78300020 EPSTEIN, JEFFREY rd Collected: 01/05/2018 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 64 Received: 01/05/2018 / 22:36 EST Gender: M Reported: 01/08/2018 / 23:26 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Endocrinology Test Name Result Reference Range Lab VITAMIN D,25-OH, TOTAL,IA | 85s 80-100 ng/mL MI Vitamin D Status 25-OH Vitamin D: Deficiency: <20 ng/mL Insufficiency: 20 - 29 ng/mL Optimal: > or = 30 ng/mL For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssureD(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs). For more information on this test, go to: http://education.questdiagnostics.com/faq/FAQ163 (This link is being provided for informational! educational purposes only.) Physician Comments: PERFORMING SITE: AT QUEST DIAGNOSTICS-ATLANTA, 1777 MONTREAL CIRCLE, TUCKER, GA 30084-6802 Laboratory Director: ANDREW N YOUNG,MD,PHD, CLIA: 1110255931 Mi QUEST DIAGNOSTICS-MIAMI, 10200 COMMERCE PARKWAY, MIRAMAR, FL 33025.3938 Laboratory Director: GLEN L. HORTIN MD PHD, CLIA: 10D0277334 TP QUEST DIAGNOSTICS-TAMPA, 4225 E FOWLER AVE. TAMPA, FL 33617-2026 Laboratory Director: GLEN L HORTIN,MD.PHD, CLIA: 1010291120 CLIENT SERVICES: 866.697.8378 SPECIMEN: MR156329E PAGE 5 OF 5 Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00305001